Compare Crispr Therapeutics AG (CRSP) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Crispr Therapeutics AG trades at $53.81 (market cap $5.23B), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| CRSP | YMAX | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $76.78 | $13.26 |
52-Week Low | $44.34 | $7.27 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
YMAX trades at $7.635, down 0.97% on the day, with a bullish technical signal but bearish moving averages. The ETF shows a pattern of weekly dividend distributions, though recent payouts have decreased from $0.15 to $0.06, indicating potential income pressure. Key technical levels show support at $7 and resistance at $8, with RSI suggesting mild overbought conditions.
The outlook for YMAX hinges on its ability to sustain distributions amid cost concerns. Risks include the fund-of-funds fee structure and market volatility. Analyst sentiment is mixed, with some highlighting income appeal but cautioning on expense drag. Upside depends on stable option income generation in varying market regimes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
